Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, London, UK.
Nat Rev Urol. 2012 Nov;9(11):652-64. doi: 10.1038/nrurol.2012.185.
Although prostate cancer is the most common malignancy to affect men in the Western world, the molecular mechanisms underlying its development and progression remain poorly understood. Like all cancers, prostate cancer is a genetic disease that is characterized by multiple genomic alterations, including point mutations, microsatellite variations, and chromosomal alterations such as translocations, insertions, duplications, and deletions. In prostate cancer, but not other carcinomas, these chromosome alterations result in a high frequency of gene fusion events. The development and application of novel high-resolution technologies has significantly accelerated the detection of genomic alterations, revealing the complex nature and heterogeneity of the disease. The clinical heterogeneity of prostate cancer can be partly explained by this underlying genetic heterogeneity, which has been observed between patients from different geographical and ethnic populations, different individuals within these populations, different tumour foci within the same patient, and different cells within the same tumour focus. The highly heterogeneous nature of prostate cancer provides a real challenge for clinical disease management and a detailed understanding of the genetic alterations in all cells, including small subpopulations, would be highly advantageous.
虽然前列腺癌是西方世界男性最常见的恶性肿瘤,但它的发展和进展的分子机制仍知之甚少。与所有癌症一样,前列腺癌是一种遗传疾病,其特征是多种基因组改变,包括点突变、微卫星变异和染色体改变,如易位、插入、重复和缺失。在前列腺癌中,但不是在其他癌中,这些染色体改变导致基因融合事件的高频发生。新型高分辨率技术的发展和应用极大地加速了基因组改变的检测,揭示了疾病的复杂性和异质性。前列腺癌的临床异质性部分可以用这种潜在的遗传异质性来解释,这种异质性在来自不同地理和种族人群的患者之间、这些人群中的不同个体之间、同一患者内的不同肿瘤病灶之间以及同一肿瘤病灶内的不同细胞之间都有观察到。前列腺癌的高度异质性给临床疾病管理带来了真正的挑战,详细了解所有细胞(包括小亚群)的遗传改变将非常有利。